These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17049971)

  • 1. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
    Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
    Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
    Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.
    Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1081-8. PubMed ID: 18180917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
    Nasu K; Abe W; Takai N; Tomonari K; Narahara H
    Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
    Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
    Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Morita S; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
    Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
    AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting recurrence of gastric cancer: the value of FDG PET/CT.
    Park MJ; Lee WJ; Lim HK; Park KW; Choi JY; Kim BT
    Abdom Imaging; 2009 Jul; 34(4):441-7. PubMed ID: 18543017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography.
    Park DH; Kim KH; Park SY; Lee BH; Choi CW; Chin SY
    Korean J Radiol; 2000; 1(1):51-5. PubMed ID: 11752929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
    Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
    Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.
    Yildirim Y; Sehirali S; Avci ME; Yilmaz C; Ertopcu K; Tinar S; Duman Y; Sayhan S
    Gynecol Oncol; 2008 Jan; 108(1):154-9. PubMed ID: 17945337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of whole body FDG-PET for recurrent biliary cancer: a multicenter study.
    Kitajima K; Murakami K; Kanegae K; Tamaki N; Kaneta T; Fukuda H; Nakajima K; Fujii H; Tateishi U; Kubota K; Suga T; Nakamoto Y
    Ann Nucl Med; 2009 Oct; 23(8):709-15. PubMed ID: 19756919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.